EXACT SCIENCES CORP (1EXAS.MI) Stock Fundamental Analysis
BIT:1EXAS - US30063P1057 - Common Stock
38.5 EUR
-1.2 (-3.01%)
Overall 1EXAS gets a fundamental rating of 3 out of 10. We evaluated 1EXAS against 74 industry peers in the Biotechnology industry. While 1EXAS seems to be doing ok healthwise, there are quite some concerns on its profitability. 1EXAS is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year 1EXAS has reported negative net income.
1EXAS had a positive operating cash flow in the past year.
In the past 5 years 1EXAS always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: 1EXAS reported negative operating cash flow in multiple years.
1.2 Ratios
1EXAS has a Return On Assets of -17.34%. This is comparable to the rest of the industry: 1EXAS outperforms 56.76% of its industry peers.
The Return On Equity of 1EXAS (-40.71%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.34% | ||
| ROE | -40.71% | ||
| ROIC | N/A |
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
1EXAS has a Gross Margin (68.19%) which is in line with its industry peers.
1EXAS's Gross Margin has declined in the last couple of years.
1EXAS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.19% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
2. Health
2.1 Basic Checks
1EXAS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for 1EXAS has been increased compared to 1 year ago.
The number of shares outstanding for 1EXAS has been increased compared to 5 years ago.
The debt/assets ratio for 1EXAS is higher compared to a year ago.
2.2 Solvency
1EXAS has an Altman-Z score of 1.04. This is a bad value and indicates that 1EXAS is not financially healthy and even has some risk of bankruptcy.
1EXAS has a Altman-Z score (1.04) which is in line with its industry peers.
1EXAS has a debt to FCF ratio of 18.77. This is a negative value and a sign of low solvency as 1EXAS would need 18.77 years to pay back of all of its debts.
1EXAS has a Debt to FCF ratio of 18.77. This is in the better half of the industry: 1EXAS outperforms 77.03% of its industry peers.
1EXAS has a Debt/Equity ratio of 0.94. This is a neutral value indicating 1EXAS is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.94, 1EXAS perfoms like the industry average, outperforming 45.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.94 | ||
| Debt/FCF | 18.77 | ||
| Altman-Z | 1.04 |
ROIC/WACCN/A
WACC8.64%
2.3 Liquidity
A Current Ratio of 2.89 indicates that 1EXAS has no problem at all paying its short term obligations.
1EXAS's Current ratio of 2.89 is fine compared to the rest of the industry. 1EXAS outperforms 66.22% of its industry peers.
1EXAS has a Quick Ratio of 2.56. This indicates that 1EXAS is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 2.56, 1EXAS is doing good in the industry, outperforming 64.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.89 | ||
| Quick Ratio | 2.56 |
3. Growth
3.1 Past
1EXAS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -465.63%.
Looking at the last year, 1EXAS shows a quite strong growth in Revenue. The Revenue has grown by 12.56% in the last year.
The Revenue has been growing by 25.78% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-465.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.89%
Revenue 1Y (TTM)12.56%
Revenue growth 3Y16.01%
Revenue growth 5Y25.78%
Sales Q2Q%15.99%
3.2 Future
The Earnings Per Share is expected to grow by 20.32% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 10.08% on average over the next years. This is quite good.
EPS Next Y89.28%
EPS Next 2Y43.73%
EPS Next 3Y30.79%
EPS Next 5Y20.32%
Revenue Next Year14.7%
Revenue Next 2Y13.51%
Revenue Next 3Y12.96%
Revenue Next 5Y10.08%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for 1EXAS. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 122.12, which means the current valuation is very expensive for 1EXAS.
Based on the Price/Forward Earnings ratio, 1EXAS is valued a bit cheaper than 74.32% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.63. 1EXAS is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 122.12 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1EXAS indicates a somewhat cheap valuation: 1EXAS is cheaper than 70.27% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, 1EXAS is valued a bit cheaper than the industry average as 79.73% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 68.12 | ||
| EV/EBITDA | 146.98 |
4.3 Compensation for Growth
1EXAS's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as 1EXAS's earnings are expected to grow with 30.79% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.73%
EPS Next 3Y30.79%
5. Dividend
5.1 Amount
No dividends for 1EXAS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIT:1EXAS (9/1/2025, 7:00:00 PM)
38.5
-1.2 (-3.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners98.76%
Inst Owner ChangeN/A
Ins Owners0.87%
Ins Owner ChangeN/A
Market Cap7.29B
Analysts85.45
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)27.73%
Min EPS beat(2)-39.07%
Max EPS beat(2)94.53%
EPS beat(4)2
Avg EPS beat(4)-333.88%
Min EPS beat(4)-1391.93%
Max EPS beat(4)94.53%
EPS beat(8)5
Avg EPS beat(8)-143.38%
EPS beat(12)9
Avg EPS beat(12)-87.39%
EPS beat(16)11
Avg EPS beat(16)-65.6%
Revenue beat(2)2
Avg Revenue beat(2)1.64%
Min Revenue beat(2)0.62%
Max Revenue beat(2)2.65%
Revenue beat(4)2
Avg Revenue beat(4)-0.05%
Min Revenue beat(4)-3.19%
Max Revenue beat(4)2.65%
Revenue beat(8)2
Avg Revenue beat(8)-0.26%
Revenue beat(12)6
Avg Revenue beat(12)1.07%
Revenue beat(16)10
Avg Revenue beat(16)1.66%
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 122.12 | ||
| P/S | 2.89 | ||
| P/FCF | 68.12 | ||
| P/OCF | 27.78 | ||
| P/B | 3.44 | ||
| P/tB | N/A | ||
| EV/EBITDA | 146.98 |
EPS(TTM)-4.66
EYN/A
EPS(NY)0.32
Fwd EY0.82%
FCF(TTM)0.57
FCFY1.47%
OCF(TTM)1.39
OCFY3.6%
SpS13.33
BVpS11.2
TBVpS-3.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.34% | ||
| ROE | -40.71% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.19% | ||
| FCFM | 4.24% |
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
F-Score4
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.94 | ||
| Debt/FCF | 18.77 | ||
| Debt/EBITDA | 35.11 | ||
| Cap/Depr | 83.3% | ||
| Cap/Sales | 6.16% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 459.82% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.89 | ||
| Quick Ratio | 2.56 | ||
| Altman-Z | 1.04 |
F-Score4
WACC8.64%
ROIC/WACCN/A
Cap/Depr(3y)84.38%
Cap/Depr(5y)130.41%
Cap/Sales(3y)7.28%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-465.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.89%
EPS Next Y89.28%
EPS Next 2Y43.73%
EPS Next 3Y30.79%
EPS Next 5Y20.32%
Revenue 1Y (TTM)12.56%
Revenue growth 3Y16.01%
Revenue growth 5Y25.78%
Sales Q2Q%15.99%
Revenue Next Year14.7%
Revenue Next 2Y13.51%
Revenue Next 3Y12.96%
Revenue Next 5Y10.08%
EBIT growth 1Y16.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year321.21%
EBIT Next 3Y82.67%
EBIT Next 5Y52.64%
FCF growth 1Y214.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y316.93%
OCF growth 3YN/A
OCF growth 5YN/A